N. Simmonds (London, United Kingdom), C. De Boeck (Leuven, Belgium), J.S. Elborn (Belfast, United Kingdom), A. Lindblad (Gothenburg, Sweden)
The relationship between daily physical activity and exercise performance in adults with cystic fibrosis
D. Savi, M. Di Paolo, N. Simmonds, P. Onorati, T. Perelli, S. Bertasi, G. Cimino, S. Quattrucci, P. Laveneziana, P. Palange (Rome, Italy; London, United Kingdom; Paris, France)
|   |
Subjective sleep quality in adults with cystic fibrosis
O. Erskine, J. Wheatley, P. Middleton (Westmead, Australia)
| |
Lung MRI findings in children with cystic fibrosis
A. Jung, C. Amaxopoulou, R. Gnannt, R. Götti, C. Bieli, R. Spinas, A. Möller, C. Kellenberger (Zurich, Switzerland)
| |
Hypoglycemia: An unrecognized problem in cystic fibrosis (CF) patients unmasked by continues glucose monitorisation (CGM)
B. Haliloglu, Y. Gokdemir, Z. Atay, S. Abali, T. Guran, F. Karakoc, R. Ersu, B. Karadag, S. Turan, A. Bereket (Istanbul, Turkey)
| |
Evaluation of the effectiveness of cyclical and constant current on sweat volume and stimulation for cystic fibroses diagnoses
C. Gomez, M. Servidoni, F. Marson, P. Canavezi, A. Vinagre, C. Pavan, M. Santos-Rodon, E. Costa, A. Ribeiro, M. Ribeiro, F. Vieira Junior, G. Hessel, C. Levy, C. Bertuzzo, S. Lorena, J. Ribeiro (Campinas, Brazil)
| |
Clinical value of lung clearance index (LCI) among patients with cystic fibrosis
E. Hatziagorou, V. Avramidou, A. Kampouras, F. Kirvasillis, J. Tsanakas (Thessaloniki, Greece)
| |
Lung clearance index predicts pulmonary exacerbations in cystic fibrosis
J. Grosse-Onnebrink, F. Stehling, U. Mellies (Münster, Essen, Germany)
| |
Modelling and simulation of experimental designs to find the best design of randomized clinical trials in a rare disease: Cystic fibrosis
P. Kurbatova, A. Bajard, H. Tiddens, V. Volpert, C. Cornu, N. Bessonov, B. Kassai, S. Chabaud, P. Nony, D. Caudri (Lyon, Bron, France; Rotterdam, Netherlands)
| |
Clinical, functional and microbiological characteristics of an adult brazilian cystic fibrosis population
S. Z. Rached, R. Athanazio, M. C. N. T. Maiorano, F. Fernandes, R. Carvalho-Pinto, A. Cukier, R. Stelmach (Sao Paulo, Brazil)
| |
Lung Clearance Index (LCI) and FEV1 on the evaluation of the effect of tobramycin solution for inhalation (TIS) among patients with cystic fibrosis
E. Hatziagorou, V. Avramidou, A. Kampouras, F. Kirvasillis, J. Tsanakas, E. Hatziagorou (Thessaloniki, Greece)
| |
Difficulties in optimizing vitamin D levels in paediatric cystic fibrosis patients
A. Mistry, R. Huggins, A. Ward, J. Bhatt (Nottingham, United Kingdom)
| |
Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF)
S. Gartner, S. Rovira, I. de Mir, A. Torrent, B. Caurín, G. Sacoto, E. Canino, A. Moreno-Galdó (Barcelona, Spain)
| |
Chest Vest therapy increases FENO and may lead to F508del CFTR maturation
N. Marozkina, L. Smith, C. Cotton, B. Gaston (Cleveland, United States Of America)
| |